

OIR 13 2006

US Form PTO/SB/08: Substitute for form 1449A/PTO

Complete if Known

| | | | |
|--|--|------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Application Number | 10/715,556 |
| | | Filing Date | November 19, 2003 |
| | | First Named Inventor | Swen HÖLDER |
| | | Art Unit | 1624 |
| | | Examiner Name | Kahsay HABTE |
| | | Attorney Docket Number | 03806.0590-00 |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 1 |
|-------|---|----|---|

| U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS | | | | | |
|---|-----------------------|---|---|---|---|
| Examiner Initials | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Issue or Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| KH ↓ | | 4,353,905 | 10-12-1982 | Sircar et al. | |
| | | 4,734,415 | 03-29-1988 | Sircar et al. | |
| | | 5,418,233 | 05-23-1995 | Linz et al. | |
| | | | | | |

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|---|-----------------------------|---|---|--------------------------|
| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Translation ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| KH ↓ | | EP 0 075 436 B1 | 03-30-1983 | Warner-Lambert Company | | English |
| | | EP 1 061 077 A1 | 12-20-2000 | Kowa Co., Ltd. | | English |
| | | EP 1 319 659 A1 | 6-18-2003 | Eisai Co., Ltd. | | English |
| | | JP 9-216883 | 08-19-1997 | Fujisawa Pharmaceutical Co. Ltd. | | Yes |
| | | WO 02/22587 A1 | 03-21-2002 | Eisai Co., Ltd. | | Abstract |
| | | WO 02/50065 A2 | 06-27-2002 | Vertex Pharmaceuticals Inc. | | English |
| | | WO 03/035065 A1 | 01-01-2003 | Aventis Pharmaceuticals | | English |
| | | WO 03/059891 A1 | 07-24-2003 | Pharmacia Corporation | | English |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|--------------------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation ⁶ |
| KH ↓ | | S. Nikoulina et al., "Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle," <i>Diabetes</i> , Vol. 51, pp. 2190-2198, July 2002 | |
| | | E. Henriksen et al., "Modulation of Muscle Insulin Resistance by Selective Inhibition of GSK-3 in Zucker Diabetic Fatty Rats," <i>Am. J. Physiol. Endocrinol. Metab.</i> , vol. 284, pp. 892-900, 2003 | |
| | | An English translation of JP 9-216883 | |
| | | An English language Patent Abstract of Japan of JP 9-216883 | |

| | | |
|--------------------|-----------------|-----------|
| Examiner Signature | Date Considered | 3/20/2006 |
|--------------------|-----------------|-----------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.